Skip to main content


Fig. 2 | Cancer Communications

Fig. 2

From: CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trial

Fig. 2

Kaplan-Meier analysis comparing the progression-free survival of patients from the CMAB009 plus irinotecan arm to those in the irinotecan-only arm only. PFS, progression free survival; HR, hazard ratio; CI, confidence intervals

Back to article page